Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting
Abstract Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations. Objectives We studied the impact of dupilumab on health care resource utilisation...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.151 |
| _version_ | 1827854499417423872 |
|---|---|
| author | Ken Igawa Hiroyuki Fujita Yuki Tajima Robert Lubwama Moataz Daoud Zhixiao Wang Kazuhiko Arima |
| author_facet | Ken Igawa Hiroyuki Fujita Yuki Tajima Robert Lubwama Moataz Daoud Zhixiao Wang Kazuhiko Arima |
| author_sort | Ken Igawa |
| collection | DOAJ |
| description | Abstract Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations. Objectives We studied the impact of dupilumab on health care resource utilisation (HCRU) and AD medication by comparing use during the 6 months either side of starting dupilumab (index) in a real‐world setting. Methods This observational, retrospective, cohort study used Japanese hospital claims data (1 April 2018 to 28 February 2019). A total of 357 patients (mean [range] age 45 [15–92] years; 65.5% male) with ≥1 AD diagnosis and ≥1 dupilumab prescription were included. Outcome variables included AD treatments and HCRU during the 6 months pre‐ and post‐index. Results The number of all‐cause hospitalisations decreased by 43.1% (from 51 in the 6 months before to 29 in the 6 months after dupilumab initiation), with a 96.0% reduction in skin/subcutaneous tissue disease‐related hospitalisations (25 to 1). Use of nonsteroidal systemic immunosuppressants, phototherapy and systemic corticosteroids decreased (by 59.8%, 59.5% and 30.6%, respectively) after dupilumab initiation. At 180 days after dupilumab initiation, 86.8% of patients were still taking dupilumab. Conclusions Overall, these results suggest that dupilumab can reduce skin/soft tissue‐related hospitalisations and use of various other AD medications in a real‐world setting. |
| first_indexed | 2024-03-12T11:23:42Z |
| format | Article |
| id | doaj.art-0a3dafca92ef47ce9e530e02bb97b583 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-03-12T11:23:42Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-0a3dafca92ef47ce9e530e02bb97b5832023-09-01T12:30:54ZengWileyJEADV Clinical Practice2768-65662023-09-012354354810.1002/jvc2.151Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world settingKen Igawa0Hiroyuki Fujita1Yuki Tajima2Robert Lubwama3Moataz Daoud4Zhixiao Wang5Kazuhiko Arima6Dokkyo Medical University Tochigi JapanSanofi K.K. Tokyo JapanSanofi K.K. Tokyo JapanSanofi Bridgewater New Jersey USASanofi Cambridge Massachusetts USARegeneron Pharmaceuticals, Inc Tarrytown New York USASanofi K.K. Tokyo JapanAbstract Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations. Objectives We studied the impact of dupilumab on health care resource utilisation (HCRU) and AD medication by comparing use during the 6 months either side of starting dupilumab (index) in a real‐world setting. Methods This observational, retrospective, cohort study used Japanese hospital claims data (1 April 2018 to 28 February 2019). A total of 357 patients (mean [range] age 45 [15–92] years; 65.5% male) with ≥1 AD diagnosis and ≥1 dupilumab prescription were included. Outcome variables included AD treatments and HCRU during the 6 months pre‐ and post‐index. Results The number of all‐cause hospitalisations decreased by 43.1% (from 51 in the 6 months before to 29 in the 6 months after dupilumab initiation), with a 96.0% reduction in skin/subcutaneous tissue disease‐related hospitalisations (25 to 1). Use of nonsteroidal systemic immunosuppressants, phototherapy and systemic corticosteroids decreased (by 59.8%, 59.5% and 30.6%, respectively) after dupilumab initiation. At 180 days after dupilumab initiation, 86.8% of patients were still taking dupilumab. Conclusions Overall, these results suggest that dupilumab can reduce skin/soft tissue‐related hospitalisations and use of various other AD medications in a real‐world setting.https://doi.org/10.1002/jvc2.151atopic dermatitisdupilumabhealth care resource utilisationhospitalisationsJapan |
| spellingShingle | Ken Igawa Hiroyuki Fujita Yuki Tajima Robert Lubwama Moataz Daoud Zhixiao Wang Kazuhiko Arima Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting JEADV Clinical Practice atopic dermatitis dupilumab health care resource utilisation hospitalisations Japan |
| title | Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting |
| title_full | Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting |
| title_fullStr | Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting |
| title_full_unstemmed | Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting |
| title_short | Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting |
| title_sort | reduction in hospitalisations with dupilumab in japanese adults with atopic dermatitis in a real world setting |
| topic | atopic dermatitis dupilumab health care resource utilisation hospitalisations Japan |
| url | https://doi.org/10.1002/jvc2.151 |
| work_keys_str_mv | AT kenigawa reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting AT hiroyukifujita reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting AT yukitajima reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting AT robertlubwama reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting AT moatazdaoud reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting AT zhixiaowang reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting AT kazuhikoarima reductioninhospitalisationswithdupilumabinjapaneseadultswithatopicdermatitisinarealworldsetting |